Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2015

Open Access 01-12-2015 | Original investigation

The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study

Authors: Jonas Malmstedt, Lars Kärvestedt, Jesper Swedenborg, Kerstin Brismar

Published in: Cardiovascular Diabetology | Issue 1/2015

Login to get access

Abstract

Background

Patients with type 2 diabetes have a high risk for early and extensive development of peripheral arterial disease (PAD) and this excess risk is not explained by increased burden of traditional atherosclerotic risk factors. Activation of the receptor for advanced glycation end products (RAGE) could be one additional mechanism for accelerated PAD and increased risk for amputation and death. We investigated the association between RAGE plasma components and the risk for PAD, amputation and death in patients with type 2 diabetes. We also estimated the rate of amputation-free survival and survival without PAD.

Methods

We investigated if plasma levels of carboxymethyl-lysine, S100A12 and endosecretory RAGE (esRAGE) were associated with two endpoints: survival without development of PAD and survival without amputation in a 12 years prospective population-based cohort of 146 patients with type 2 diabetes, free from PAD at inclusion. Influence of baseline plasma levels of RAGE ligands (individually and combined by a RAGE-score) were evaluated for both endpoints in the Cox-regression analysis.

Results

106 patients survived without amputation and 93 survived without signs of PAD during follow up. Higher levels of S100A12 and RAGE-score were associated with increased risk for amputation or death, hazard ratios (HR) 1.29; 95% confidence interval (CI) [1.04, 1.59] and 1.79; 95% CI [1.07, 2.99] and with increased risk for PAD or death, HR 1.22; 95% CI [1.00, 1.49] and 1.56; [1.00, 2.44] after adjustment for age and sex. The effect was decreased after adjustment for Framingham cardiovascular disease score: risk for amputation or death, HR 1.17; 95% CI [0.94, 1.46] and 1.54; [0.95, 2.49], and risk for PAD or death, HR 1.12; 95% CI [0.91, 1.38] and 1.38; [0.91, 2.11] for S100A12 and RAGE-score respectively. The incidence for amputation or death was 2.8 per 100 person-years; 95% CI [2.0, 3.7] and the incidence rate for PAD or death was 3.6 per 100 person-years; 95% CI [2.7, 4.8].

Conclusion

Higher plasma levels of S100A12 and the combined effect (RAGE-score) of esRAGE, carboxymethyl-lysine and S100A12 seem to be associated with shorter PAD- and amputation-free survival in patients with type 2 diabetes. This may indicate a role for S100A12 in PAD by activation of the RAGE system.
Appendix
Available only for authorised users
Literature
1.
Leibson CL, Ransom JE, Olson W, Zimmerman BR, O’Fallon WM, Palumbo PJ (2004) Peripheral arterial disease, diabetes, and mortality. Diabetes Care 27(12):2843–2849PubMedCrossRef
2.
Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E et al (2007) Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis 190(1):84–89PubMedCrossRef
3.
Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR (2006) HbA1c and peripheral arterial disease in diabetes: the atherosclerosis risk in communities study. Diabetes Care 29(4):877–882PubMedCrossRef
4.
Ogren M, Hedblad B, Engstrom G, Janzon L (2005) Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study ‘Men born in 1914’ from Malmo, Sweden. Eur J Vasc Endovasc Surg 29(2):182–189PubMedCrossRef
5.
Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR (2002) UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25(5):894–899PubMedCrossRef
6.
Zander E, Heinke P, Reindel J, Kohnert KD, Kairies U, Braun J et al (2002) Peripheral arterial disease in diabetes mellitus type 1 and type 2: are there different risk factors? Vasa 31(4):249–254PubMedCrossRef
7.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169PubMedCentralPubMedCrossRef
8.
MacGregor AS, Price JF, Hau CM, Lee AJ, Carson MN, Fowkes FG (1999) Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study. Diabetes Care 22(3):453–458PubMedCrossRef
9.
Major AS, Harrison DG (2011) What fans the fire: insights into mechanisms of inflammation in atherosclerosis and diabetes mellitus. Circulation 124(25):2809–2811PubMedCentralPubMedCrossRef
10.
Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563–1574PubMedCrossRef
11.
Neeper M, Schmidt A, Brett J, Yan S, Wang F, Pan Y et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21):14998–15004PubMed
12.
Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM (2000) RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 26(5):485–493PubMedCrossRef
13.
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318(20):1315–1321PubMedCrossRef
14.
Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34(34):10872–10878PubMedCrossRef
15.
Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE et al (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30(10):2579–2582PubMedCrossRef
16.
Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S et al (1999) N epsilon-(Carboxymethyl)Lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274(44):31740–31749PubMedCrossRef
17.
Hsieh HL, Schafer BW, Weigle B, Heizmann CW (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 316(3):949–959PubMedCrossRef
18.
Koyama H, Shoji T, Fukumoto S, Shinohara K, Shoji T, Emoto M et al (2006) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27:147–153PubMedCrossRef
19.
Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H et al (2004) Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 89(11):5423–5428PubMedCrossRef
20.
Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP (1999) The role of oxidative stress and NF-kappaB activation in late diabetic complications. BioFactors 10(2–3):157–167PubMedCrossRef
21.
Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr et al (2001) Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21(6):905–910PubMedCrossRef
22.
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C et al (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105(7):816–822PubMedCrossRef
23.
Schmidt AM, Yan SD, Wautier JL, Stern D (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84(5):489–497PubMedCrossRef
24.
Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H et al (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18(10):1385–1396PubMedCrossRef
25.
Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370(Pt 3):1097–1109PubMedCentralPubMedCrossRef
26.
Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y et al (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28(11):2716–2721PubMedCrossRef
27.
Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25(12):2587–2593PubMedCrossRef
28.
Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A et al (2006) Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91(11):4628–4634PubMedCrossRef
29.
Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y et al (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin Biochem 41(12):981–985PubMedCrossRef
30.
Mahajan N, Malik N, Bahl A, Dhawan V (2009) Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 207(2):597–602PubMedCrossRef
31.
Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ et al (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24(7):1266–1271PubMedCrossRef
32.
Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E et al (2011) Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra 1(1):242–250PubMedCentralPubMedCrossRef
33.
Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH et al (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 34(2):442–447PubMedCentralPubMedCrossRef
34.
Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A et al (2011) The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabetes Complications 25(2):97–106PubMedCrossRef
35.
Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A et al (2009) Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 32(2):317–322PubMedCentralPubMedCrossRef
36.
Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–the design and analysis of cohort studies. IARC Sci Publ 82:1–406
37.
Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8):857–872PubMedCrossRef
38.
39.
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753PubMedCrossRef
40.
41.
Boyles AL, Harris SF, Rooney AA, Thayer KA (2011) Forest plot viewer: a new graphing tool. Epidemiology 22(5):746–747PubMedCrossRef
42.
Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P et al (2010) Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 5(12):2213–2219PubMedCentralPubMedCrossRef
43.
Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T et al (2011) Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6(4):718–723PubMedCentralPubMedCrossRef
44.
Callaghan BC, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffet H et al (2011) Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 34(3):635–640PubMedCentralPubMedCrossRef
45.
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32(11):1345–1361PubMedCentralPubMedCrossRef
46.
47.
Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T (2006) Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 3(1):73–77PubMedCrossRef
48.
Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S (2014) Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol 13:60PubMedCentralPubMedCrossRef
49.
Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 12:125PubMedCentralPubMedCrossRef
50.
Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S et al (2013) Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 12:5PubMedCentralPubMedCrossRef
51.
Skrha J Jr, Muravska A, Flekac M, Horova E, Novak J, Novotny A et al (2014) Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes. Physiol Res 63(Suppl 2):S283–S291PubMed
52.
Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M (2003) Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 26(4):1241–1245PubMedCrossRef
53.
Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL et al (2005) Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 180(2):389–397PubMedCrossRef
54.
Groenwold RH, Klungel OH, Grobbee DE, Hoes AW (2011) Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol 26(8):589–593PubMedCentralPubMedCrossRef
55.
Stang A, Poole C, Kuss O (2010) The ongoing tyranny of statistical significance testing in biomedical research. Eur J Epidemiol 25(4):225–230PubMedCrossRef
56.
Cumming G, Finch S (2005) Inference by eye: confidence intervals and how to read pictures of data. Am Psychol 60(2):170–180PubMedCrossRef
57.
Metadata
Title
The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study
Authors
Jonas Malmstedt
Lars Kärvestedt
Jesper Swedenborg
Kerstin Brismar
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2015
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-015-0257-5

Other articles of this Issue 1/2015

Cardiovascular Diabetology 1/2015 Go to the issue

Original investigation

Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension

Original investigation

Activation of TRPV1 channel by dietary capsaicin improves visceral fat remodeling through connexin43-mediated Ca2+ Influx

Original investigation

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats

Original investigation

Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy

Original investigation

Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: a case control study

Original investigation

SIRT1 protects against myocardial ischemia–reperfusion injury via activating eNOS in diabetic rats
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits